- Home
- SNTG vs ALZN Comparison
SNTG vs ALZN Comparison
Compare SNTG & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- ALZN
- Stock Information
- Founded
- SNTG 2009
- ALZN 2016
- Country
- SNTG China
- ALZN United States
- Employees
- SNTG N/A
- ALZN N/A
- Industry
- SNTG Finance: Consumer Services
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- SNTG Finance
- ALZN Health Care
- Exchange
- SNTG Nasdaq
- ALZN Nasdaq
- Market Cap
- SNTG 6.1M
- ALZN 6.9M
- IPO Year
- SNTG 2021
- ALZN 2021
- Fundamental
- Price
- SNTG $2.25
- ALZN $1.64
- Analyst Decision
- SNTG
- ALZN
- Analyst Count
- SNTG 0
- ALZN 0
- Target Price
- SNTG N/A
- ALZN N/A
- AVG Volume (30 Days)
- SNTG 19.9K
- ALZN 361.1K
- Earning Date
- SNTG 10-29-2024
- ALZN 12-13-2024
- Dividend Yield
- SNTG N/A
- ALZN N/A
- EPS Growth
- SNTG N/A
- ALZN N/A
- EPS
- SNTG N/A
- ALZN N/A
- Revenue
- SNTG $146,554.00
- ALZN N/A
- Revenue This Year
- SNTG N/A
- ALZN N/A
- Revenue Next Year
- SNTG N/A
- ALZN N/A
- P/E Ratio
- SNTG N/A
- ALZN N/A
- Revenue Growth
- SNTG N/A
- ALZN N/A
- 52 Week Low
- SNTG $1.47
- ALZN $1.40
- 52 Week High
- SNTG $8.45
- ALZN $33.00
- Technical
- Relative Strength Index (RSI)
- SNTG 53.72
- ALZN 40.84
- Support Level
- SNTG $2.07
- ALZN $1.58
- Resistance Level
- SNTG $2.27
- ALZN $1.90
- Average True Range (ATR)
- SNTG 0.18
- ALZN 0.14
- MACD
- SNTG -0.01
- ALZN 0.05
- Stochastic Oscillator
- SNTG 29.22
- ALZN 39.53
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.